Recent Updates
Recently added Catalysts
ALT

Altimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield, a Single Dose Intranasal Anthrax Vaccine Candidate

Tuesday, June 30, 2020 1 min read
Key Takeaway: Altimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield, a Single Dose Intranasal Anthrax Vaccine Candidate

Full Press Release Details

Altimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield, a Single Dose Intranasal Anthrax Vaccine Candidate.
Tags: ALT Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jun 30, 2020